Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients

Journal of Hepatology

Volumn 26, Issue 4, 1997, Pages 871-879

  Velussi, Mario ^a   Cernigoi, Anna Maria ^a   Ariella, De Monte ^a   Dapas, Francesco ^a   Caffau, Cristina ^b   Zilli, Mario ^b  

^a Anti Diabet Ctr Monfalcone Hosp   (Italy)

^b Ctrl Anal Lab Monfalcone Hospital   (Italy)

Author keywords

anti oxidizing drug; cirrhosis; diabetes; insulin resistance; lipoperoxidation; silymarin

Indexed keywords

ANTIOXIDANT; FREE RADICAL; INSULIN; MALONALDEHYDE; SILYMARIN;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0030907984     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80255-3     Document Type: Article

References (59)

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1979;1039.
2. Raven MG, Bernstein R, Davis B, Olefsky JM. Nonketotic diabetis mellitus: insulin deficiency or insulin resistance? Am J Med. 60:1976;80-88.
3. Eriksson J, Franssila-Kallunki A, Saloranta C, et al. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med. 321:1989;337-343.
4. Rizza RA, Mandarino LJ, Genest J, et al. Production of insulin resistance by hyperinsulinemia in man. Diabetologia. 28:1986;70-78.
5. De Fronzo R. The triumvirate: beta cell, muscle, liver. Diabetes. 37:1988;667-687.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
7. De Fronzo RA, Ferranini E. Insulin resistance. Diabetes Care. 14:1992;173-194.
8. Koltermann OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. Receptor and post-receptor defect contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest. 68:1981;657-964.
9. Henry RR, Brillon D, Matthaei S, Freidenberg GR. Cellular mechanism of insulin resistance in non-insulin dependent (type II) diabetes. Am J Med. 85:1988;86-105. (Suppl.5 A).
10. Riggio O. Glucose intolerance in liver cirrhosis. Metabolism. 31:1982;627-340.11.
11. Johnston DG. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet. i:1977;10-12.
12. Greco AV. Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis. Diabetologia. 17:1979;23-28.
13. Shankar TP. Elevated growth hormone levels and insulin resistance in patients with cirrhosis of the liver. Am J Med Sci. 291:1986;248-254.
14. Proietto J, Dudley FJ, Aitken P, Alford FP. Hyperinsulinemia and insulin resistance of cirrhosis: the importance of insulin hypersecretion. Clin Endocrinol. 21:1984;657-665.
15. Buzzelli G. Intolleranza glucidica e cirrosi epatica. Liver News. 3:1991;1-7.
16. Mutig D. Interactions entre la function hépatique et le diabéte sucré. Hexagone. 8:1980;11.
17. Kingston ME, Ashraf M, Atiyeh M, Donnelly RI. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology. 87:1984;688.
18. Bonora E, Orioli S, Coscelli C, Buzzelli G, Gentillini P, Butturini U. Possible role of insulin, glucagon, growth hormone and free fatty acids in the pathogenesis of insulin resistance of subjects with chronic liver disease. Acta Diabet Lat. 21:1984;241.
19. Sotaniemi EO, Keinanen K, Lahtela JT, Arranto AJ, Kairalverma M. Carbohydrate intolerance associated with reduced hepatic glucose phosphorylating and releasing enzyme activities and peripheral insulin resistance in alcoholics with liver cirrhosis. J Hepatol. 1:1985;277-290.
20. Iversen J, Vidstrup H, Tygstrup N. Insulin resistance in alcoholic cirrhosis: decreased tissue sensitivity and decreased maximal tissue responsiveness to insulin. Hepatology. 2:1982;176-184.
21. Blei A, Robbinson DC, Drobney E, Baumann G, Rubinstein AH. Insulin resistance and insulin receptors in hepatic cirrhosis. Gastroenterology. 23:1982;1191-1199.
22. Videla LA, Valenzuela A. Alcohol ingestion, liver glutathione and lipoperoxidation: metabolic interrelations and pathological implications. Life Sci. 31:1982;2395-2407.
23. Carducci Artenisio A. Insulina e C peptide in pazienti con cirrosi epatica. G Ital Diabetol. 4:1984;261-268.
24. Kasperska-Czyzykowa T. Serum levels of true insulin, C-peptide and proinsulin in peripheral blood of patients with cirrhosis. Diabetologia. 25:1982;185-187.
25. Shaw S, Jayatilleke E, Bossa WA, Gordon ER, Lieber CS. Ethanol-induced lipid peroxidation potentiation by long term alcohol feeding and attenuation by methionine. J Lab Clin Med. 98:1981;417-425.
26. Shaw S, Rubin KP, Lieber CS. Depressed hepatic glutathione and increased diene conjugates in alcoholic liver disease: evidence of lipid peroxidation. Dig Dis Sci. 28:1983;585-589.
27. Jewell SA, Di Monte D, Gentile A, Guglielmi A, Altomare A, Albano O. Decreased hepatic glutathione in chronic alcoholic patients. J Hepatol. 3:1986;1-6.
28. Ivanov V, Rahier J, Lauweryus R. Lipid peroxidation in acryonil-treated rats evidenced by elevated ethane production. J Appl Toxicol. 9:1989;353-358.
29. Firhust S, Baber DJ, Clark B, Horton AA. Studies on paracematol-induced lipid peroxidation. Toxicology. 23:1982;254-9.30.
30. Rosen GM, Singletary WV, Ranckman EJ, Paul G. Acetaminophen hepatotoxicity: an alternative mechanism. Biochem Pharmacol. 32:1983;2053-2059.
31. Prior WA. The role of free radicals reaction in biological systems. Free Rad Biol. 1:1976;1.
32. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia. 36:1993;1119-1125.
33. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 40:1991;405-412.
34. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Lefebre PJ. Metabolic control may influence the increased superoxide anion generation in diabetic serum. Diabet Med. 8:1991;540-542.
35. Barrowcliffe TW, Gutteridge JM, Gray E. Oxygen radicals, lipid peroxidation and the coagulation system. Agent Actions. 22:1987;347-348.
36. Jain SK, Levine SN, Duett J, Hollier B. Reduced vitamin E and increased lipofuscin products in erythrocytes of diabetic rats. Diabetes. 40:1991;1241-1244.
37. Karpen CW, Pritchard KA, Arnold JH, Cornwell DG, Panganamala RV. Restoration of prostacyclin thromboxane A2 balance in the diabetic rat: influence of dietary vitamin E. Diabetes. 31:1982;947-951.
38. Altavilla R.A., Procacci V, Cirelli F, Chicco D, Ciannamea F, Angelini P, Vendemiale G, Altomare E. Diabete mellito e lipoperossidazione. Gazz Med It- Arch Sci Med. 151:1992;93-97.
39. Pozzilli P. Free oxygen radical scavengers: their use in pretype I diabetes. IDIG Newsletter. 4:1990;1-2.
40. Giordano C, Pantó F, Amato MP, et al. La terapia combinata con GSH ed immunomodulatori influenza la comparsa di remissione clinica nel diabete di tipo I (IDDM) all'insorgenza. Atti del XXII Congresso Nazionale della Societá Italiana per lo Studio del metabolismo normale e patologico Palermo. 1989 17-18 November;247.
41. Sonnenbichler L, Zetl I. Stimulating influence of a flovolignane derivative on proliferation, RNA synthesis and protein synthesis in liver cells. Assessment and Management of Hepatobiliary Diseases. 1987;265-272 Springer Verlag, Berlin-Heidelberg.
42. Mourelle M, Muriel L, Favari L, Franco T. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol. 3:1979;183-191.
43. Feher J, Deak G, Muzes G. The hepatoprotective effect of treatment with silymarin in patients with chronic alcoholic liver disease. Orovosi Hetilap (Medical Weekly). 130:1989;2723-2727.
44. Feher J. Silymarin as free radical scavenger in toxic liver lesions. Abstract from VI Biennil Meeting of the International Society for Free Radical Research. 1992 June 16-20;. Turin.
45. Vendemiale G, Altomare E, Grattagliano I, Albano O. Increased plasma levels of glutathione and malondialdehyde after acute ethanol ingestion in humans. J Hepatol. 9:1989;359-365.
46. Bird RP, Draper HH. Comparative studies on different methods of malondialdehyde determination. Colowick SP, Kaplan OP. Methods in Enzymology. 1984;299-315 Springer Verlag, Berlin, Heidelberg.
47. Conti M, Morand P, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clin Chem. 37:1991;1273-1275.
48. Minisci F, Citterio A, Ciani D. Antioxidant activity of silymarin. Abstract from VI Biennial Meeting of International Society for Free Radicals Research. 1992 June 16-20;. Turin.
49. Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 109:1995;1941-1949.
50. Ramellini G, Meldolesi I. Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin. Arzneimittelforschung. 24:1974;806-808.
51. Faulstich H, Jahn W, Wieland T. Silybin inhibition of amatoxin uptake in the perfused rat liver. Arnsneimittelforschung. 30:1980;452-454.
52. Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experientia. 35:1979;1548-1550.
53. Feher J, Lang K, Neksam G, et al. Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med Hung. 45:1988;265-276.
54. Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Meth Find Exptl Clin Pharmacol. 6:1984;655-661.
55. Flory PJ, Krug G, Lorenz D, Mennicke WH. Studies on elimination of silymarin in cholecytectomized patients. Plant Med. 38:1980;227-237.
56. Stanton A, Glantz. Primer of Biostatistics. 1987;McGraw Hill Inc. New York.
57. Cavallo-Perin P. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest. 75:1985;1659-1666.
58. Nygren A. Insulin uptake by the human alcoholic cirrhotic liver. Metabolism. 34:1985;48-52.
59. Cavallo-Perin P. Feedback inhibition of insulin secretion is altered in cirrhosis. J Clin Endocrinol Metab. 63:1986;1023-1027.